Cerebral Palsy Patient Still Improving after 2nd Round of Stem Cells in Germany

Dusseldorf, Germany (PRWEB) January 12, 2010

Three year-old Sophia Chang from Woodland Hills, California, is continuing to improve following her second stem cell treatment since March 2008 for cerebral palsy at the XCell-Center in Dusseldorf, Germany.

Sophia suffers from ataxic cerebral palsy, a condition that was brought due to a low fetal heart rate. The cause of her low heart rate remains a mystery. Her greatest difficulties are motor planning and execution ? getting her body to do what she wants it to do.

??We found out about XCell-Center and were excited to learn that we would be able to safely remove stem cells from her own bone marrow and re-inject them into her spinal fluid? We booked the (first) procedure for March 2008 when she was 23 months,? said Ellen Chang, Sophia?s mother.

Sophia received her first treatment via lumbar puncture, a procedure by which stem cells are injected into the spinal fluid under general anesthesia (for small children). The stem cell implantation procedure takes about 30 minutes. Total cost for bone marrow collection, laboratory processing and implantation is 9,000 Euros.

?? Things we noticed within a few weeks was that she developed a protective reaction when falling (we never needed to put the helmet back on once we got back home), she was able to chew foods and had more of an interest in foods (fries, peas, pretzels) within a week of the procedure. She seemed to just be more aware of everything and she played with toys more purposefully,? Mrs. Chang commented.

Since her second treatment in November 2009, Sophia has continued to improve. ??already we have noticed that her drooling has almost stopped completely and that she has acquired many new sounds and words following our second trip. In addition her words sound much clearer. She is much more motivated to use her words and will repeat many words that she hears-I think she even surprises herself when she realizes she can produce a sound she wasn?t able to just a few weeks ago,? added Mrs. Chang. Sophia?s entire story can be read at http://www.xcell-center.com/patient-stories/cerebral-palsy/sophia-chang.aspx

The XCell-Center center has treated almost 200 cerebral palsy patients by lumbar puncture since opening its doors in 2007. Patient follow-up statistics show that, overall, 2 out of 3 patients reported improvements following treatment.

In 2009, the XCell-Center treated its first patients via neuro-endoscopic autologous stem cell implantation (NEASCI?). This innovative technique allows neurosurgeons to implant stem cells directly into the fluid spaces that surround a patient?s brain thus achieving more accurate targeting of stem cells than with other implantation methods such as intrathecal or intravenous injection. All XCell-Center patients are treated with their own bone marrow-derived stem cells.

?So far, we have seen very promising results from patients we have treated via NEASCI. We expect this trend to continue and aim to release follow-up statistics in late 2010 or early 2011,? said Dr. Ute Tamaschke, the pediatric neurosurgeon who performs NEASCI procedures at the XCell-Center in Dusseldorf, Germany.

About the XCell-Center

The XCell-Center operates treatment centers in Cologne and Dusseldorf, Germany. It is the first privately-owned clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law and European guidelines. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.

The XCell-Center also treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Cerebral Palsy, Autism, Spinal Cord Injuries, Orthopedic diseases, Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson’s, Alzheimer’s and several eye diseases.

For more information on Stem Cell Therapy:

XCell-Center Website: http://www.xcell-center.com

XCell-Center GmbH

at the Institute for Regenerative Medicine

Am Heerdter Krankenhaus 2

40549 Dusseldorf, Germamy

Phone: 1-866-680-8202 (USA Toll-Free) (+49) 0221-802-5095 (Germany)

Fax:

PET Scans May Help Diagnose Movement Disorders


Manhasset, NY (Vocus) January 13, 2010

Can brain scans help diagnosis Parkinson?s disease at the onset of symptoms? One clever way to know for sure is to take snapshots of the brain at the time of the first symptoms of tremor or rigidity, and follow the patients over the years to see whether the diagnosis was correct. About 10 to 20 percent of patients initially thought to have Parkinson?s suffer from another movement disorder.

?This is a big problem for physicians,? said David Eidelberg, MD, head of the Center for Neurosciences at The Feinstein Institute for Medical Research in Manhasset, NY. ?The treatments for Parkinson?s will not work for these patients and they can cause their own side effects.?

Dr. Eidelberg and his colleagues have used brain scans to identify the networks involved with three different neurological conditions ? Parkinson?s, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). They designed a study to follow 167 patients over three years to figure out whether the initial brain scan could be used to accurately predict the cause of the symptoms. This information is critical in making treatment decisions.

The researchers calculated the odds of having each of the three diseases based on the findings from fluoro-deoxy-glucose (FDG) positron emission tomography, a technology that images glucose metabolism. They found that FDG PET scan can identify what kind of movement disorder a patient has ? something that now can only be assessed after years of clinical follow-up. ?Accurate diagnosis is key,? said Dr. Eidelberg. Nine people died during the course of the study and an autopsy substantiated the imaging diagnosis.

?It is important to provide patients with an early diagnosis to ensure proper treatment,? said Dr. Eidelberg. ?Also, if people are enrolled in clinical trials for Parkinson?s treatments, we want to know that we have enrolled the right patients.?

?The pathology is totally different but the earliest symptoms are so similar,? said Chris C. Tang, MD, the lead investigator of the study. Patients in the study were treated by movement disorder specialists, and after almost three years, the final diagnoses were matched with the initial findings on the brain scans. There was a 98 percent match suggesting that the scans could be used with great accuracy to diagnose correctly very early in the disease process.

The findings were published in the February edition of The Lancet Neurology. Dr. Eidelberg said that PET imaging can help clinicians more accurately diagnose Parkinson?s and other atypical movement disorders that share symptoms.

The researchers have mapped out distinct brain networks for each of the movement disorders. The studies suggest that MSA and PSP progress much faster than Parkinson?s. There are no effective treatments for MSA or PSP and using medicines for Parkinson?s disease can make things worse.

PET is an expensive tool and is not used routinely to help diagnosis Parkinson?s. They are expanding the study to include a larger number of patients.

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson’s disease, Alzheimer?s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

###







More Alzheimer Disease Press Releases

National Silver Alert

Palm Harbor, FL (PRWEB) January 13, 2010

The National Silver Alert Personal GPS Tracker, powered by Birds Eye Global Tracking, will help give caregivers peace of mind, while allowing those with Alzheimer?s, Dementia and other cognitive disorders to remain active and independent.

The device, no larger than a set of keys, can locate a person in 60 seconds with pinpoint accuracy. The tracker provides real-time location reports every two minutes, as well as a Geofence feature that sends alerts if the person crosses the boundary of their pre-defined area. A direct GPRS data connection provides the most accurate and reliable tracking data available in today?s market.

Neil Arfmann, President of National Silver Alert Program said, ?We chose this particular device because it is accurate, user-friendly, affordable and no installation is required?.

The device can be worn on a belt clip, placed in a purse, or placed anywhere because of its compact size. It can be plugged into an automobile cigarette lighter or 12 V accessory socket for charging during use. Most importantly, a caregiver can log into any internet ready PC to pinpoint the exact location of their loved one.

One of the most life-threatening symptoms of Alzheimer?s disease is wandering. Statistics show that approximately 60% of those with the disease will wander. If a person wanders once, they will most likely wander again. If not found within 24 hours, approximately 50% of wanderers may suffer serious injury or death.

The National Silver Alert Personal GPS Tracker can help ensure that a loved one is found as quickly as possible should they wander.

The National Silver Alert Program, introduced on October 1, 2009, has received much praise and success. The program was developed to provide vital information to authorities to assist in the search and safe recovery of individuals with Alzheimer?s, Dementia and other cognitive disorders and quickly reunite them with their loved ones.

For more information, please visit http://www.nationalsilveralert.com

###







Find More Alzheimer Disease Press Releases

Keep Your Sweetheart Heart Healthy

Baltimore, MD (PRWEB) January 14, 2010

If “love is never having to say you’re sorry,” true love must be “never letting your sweetheart consume unhealthy fats.” So says nutritionist Sue Canonico, R.D. who offers some great tips for February, American Heart Month.

“About every 25 seconds, an American will have a coronary event,” notes Canonico. “Many of the heart attacks, the most common form of heart disease, will be among baby boomers, who dated when the movie ‘Love Story’ with its memorable line about love and being sorry was in the theaters. Fortunately, there are ways to avoid the heartbreak that comes with losing a loved one to coronary disease. Some are just simple adjustments to daily recipes, such as substituting extra virgin olive oil for butter, margarine and less healthy cooking oils. Others are focusing on additional aspects of the Mediterranean Diet, such as eating fruits, vegetables and fish, and getting in some daily exercise.”

A recent study that followed over 23,000 healthy Greek men and women for over eight and a half years found a fourteen percent lower mortality for those who adhered to the Med Diet over those who did not. For thousands of years, olive oil has been used almost exclusively at meals in the Mediterranean region. Here in America, extra virgin olive oil was introduced nationally by Pompeian, a company founded at the start of the 20th century.

Nutritionist Canonico notes that eating healthy has greater significance for baby boomers because the economic downturn has put many of them under greater stress, and a large number of them need to remain in the workforce to make up for financial setbacks that their retirement funds experienced.

As scientists began looking at longevity, The Mediterranean Diet was recognized as a healthier way to eat because individuals from that region tend to have fewer heart problems and live longer. The Med Diet contains less cholesterol and has more healthy fats, including monounsaturated fats, such as olive oil, and polyunsaturated fats, which contain the beneficial omega-3 fatty acids found in fish, walnuts, and other sources. The Med Diet avoids saturated animal and dairy fats as well as hydrogenated oils containing trans-fatty acids, both of which contribute to heart disease. Olive oil’s monounsaturated fat can help reduce LDL cholesterol levels when used in place of saturated or trans fats.

“Many people never think about using olive oil at breakfast,” reflected Canonico, “but if you bake your morning muffin, olive oil can be used in the recipe or you can brush it on your whole-grain toast. At lunch you can have a salad with olive oil dressing, and at dinner you enjoy it in sauces, marinades, or with saut

HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.


Mountain View, CA (PRWEB) January 18, 2010

Today at the SharpBrains Global Virtual conference, HAPPYneuron Inc. announce the launch of HAPPYneuron PRO, an online professional destination that delivers managed cognitive therapies for impairments caused by neurotraumatic, neuropsychiatric and neurodegenerative conditions such as Traumatic Brain Injury Traumatic Brain Injury (TBI), Stroke, Schizophrenia, Depression, Mild Cognitive Impairment (MCI), Alzheimer’s disease and more.

The HAPPYneuron PRO online platform today hosts two programs, Rehabilitation and Schizophrenia, with many more available in the coming months. The Rehabilitation program Rehabilitation program enables the ultimate in customizability for unique patient needs. It has been designed by Dr. Bernard Croisile, M.D. Neurology, Ph.D. Neuropsychology, and the exercises have been used in France for over 7 years by cognitive therapists. The Schizophrenia program Schizophrenia program is a complete cognitive cross training program, designed to address the most debilitating cognitive impairments experienced by patients with schizophrenia. The Schizophrenia program was designed in partnership with specialists form the Lausanne Hospital, Switzerland, validated by scientific research and in use by a number of clinics in France, Switzerland and USA.

Each HAPPYneuron PRO program provides a series of cognitive stimulation exercises in the form of interactive FLASH games each designed to target a particular set of cognitive functions and to heighten patient engagement. Cognitive skills stimulated include memory, attention, language, visual-spatial skills and executive functions. “The HAPPYneuron PRO platform delivers highly engaging cognitive skills training programs. Our patients are motivated to work on these web-based exercises because of the appeal of the exercises themselves, and because they are able to track their own progress and performance.” said Enid Gertmenian, LMSW, Lieber Recovery and Rehabilitation Clinic, New York City.

The HAPPYneuron PRO cognitive rehab tools cognitive rehab tools harness the power of the web to enable clinicians to create accounts for their patients and assign an appropriate cognitive training program for their particular condition. The clinician can monitor the patient’s program compliance and performance via the professional interface and gain objective performance measurements. Further, the clinician or researcher can customize the treatment program, and supplement in-office rehab with in-home exercises, thus reducing cost and facilitating a more patient-centric cognitive stimulation program. “The advantage of the HAPPYneuron PRO platform is that it allows individuals to receive a more consistent dose of cognitive enhancement, thereby enabling the flexibility to design innovative research studies not previously possible.” said Christopher R. Bowie, PhD, Dept Psychiatry & Psychology, Queen’s University, Ontario, Canada.

HAPPYneuron PRO professional destination is designed for individual therapist practices and large hospital systems alike. Free 30-day trials are available for all qualified professionals. To learn more, visit http://www.happyneuronpro.com.

About HAPPYneuron, Inc.:

A pioneer in brain training and rehabilitation solutions, HAPPYneuron offers a broad range of scientifically validated, personalized programs in multi-media formats for children, adults and seniors. HAPPYneuron was co-founded by internationally acclaimed and award winning neurologist, Bernard Croisile, MD PhD, and is dedicated to improving cognitive health through evidence based products for individuals and cognitive therapy professionals worldwide. HAPPYneuron is a majority owned subsidiary of Scientific Brain Training (NYSE Euronext: MLSBT). To learn more about HAPPYneuron, Inc. visit http://www.happy-neuron-pro.com.

This press release was distributed through PR Web by Senior Care Marketer (SeniorCareMarketer: http://www.SeniorCareMarketer.com) on behalf of the company listed above.

###







Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer


Calabasas Hills, Calif. (Vocus) January 20, 2010

The ALS Association, the nation?s leader in the fight against the disease ALS (amyotrophic laterals sclerosis) announced today that it has appointed Gordon S. LaVigne as chief development and communications officer. He will work out of The Association?s new headquarters in Washington, D.C.

LaVigne most recently was the vice president of business development for the Autism Society of America. He was responsible for nationwide fundraising in this position and headed all philanthropic and revenue producing activities.

Prior to the Autism Society of America, LaVigne was the senior director of development and director of planned giving for the Alzheimer?s Association National Office. One of his primary responsibilities in this position was serving as the fundraising liaison to 78 chapters, setting strategic fundraising direction and collaborations that resulted in a $ 160 million combined budget between the chapters and the national organization.

The appointment of LaVigne concludes a comprehensive search for the most qualified candidate.

?We needed to restructure our development department and Gordon?s background is the perfect match for this organization,? Jane H. Gilbert, president and CEO of The Association. ?His expertise in chapter relations with the Alzheimer?s Association makes made him the ideal choice for working with us and our chapters. His background in terms of working with major gift officers and his expertise with a nationwide organization will help elevate the success of our development efforts in the pursuit of our ultimate goal ? to create a world without ALS.?

In this position, LaVigne is responsible for managing all revenue producing activities and external relations that promote awareness about ALS and support the mission of The Association.

?I am thrilled about the opportunity to join The ALS Association,? LaVigne said. ?I have great respect for the organization?s impact on supporting individuals affected by ALS and directing an

international research program. The ALS Association is a proven leader, and I look forward working to grow its philanthropic support to serve more people affected by ALS.?

LaVigne holds a master?s degree in education from the University of Vermont in Burlington, Vt., and a bachelor?s degree in science and psychology from Lewis & Clark College in Portland, Ore.

ALS, which took the life of baseball legend Lou Gehrig, is a progressive, neurodegenerative disease that annually afflicts 30,000 people in the United States. ALS is commonly referred to as Lou Gehrig?s Disease.

The ALS Association is the only non-profit organization fighting Lou Gehrig?s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure.

For more information about The Association, visit the organization?s Web site at http://www.alsa.org or call (800) 782-4747.

Contact:

The ALS Association

Gary Wosk, Manager, Media Relations

(818) 587-2241

The ALS Association

Greg Cash, Director, Communications

(818) 587-2243

###







Find More Alzheimer Disease Press Releases

Nor Eagle Release Fumbers – “An Alzheimer-Fighting iPhone game for Steve Jobs”


Oslo, Norway (PRWEB) January 20, 2010

Norwegian iPhone Developer Nor Eagle, today released their latest iPhone game Fumbers. Fumbers is a reflex- and memory-testing game targeted at Steve Jobs according to Nor Eagle CEO, T. Benjamin Larsen. “Our aim was to create a game that anyone and everyone would enjoy playing. The rumor has it Steve Jobs loves video games as much as he loves wearing Hawaiian shirts, so he seemed like the perfect target for Fumbers,” he said. “Now, it might never happen, but I believe that if he ever comes across Fumbers he will find it entertaining. We really think Fumbers is the game to show any parent, grandparent, partner, or anyone else that fail to understand the appeal of video gaming.”

To achieve their goal Nor Eagle have shaped the game around the psychological principle that the human mind craves to be challenged and loves being rewarded. “Finding the right balance is always one of the most difficult aspects of game making. The trick is finding the sweet-spot where the player feels challenged yet able to master the task at hand. I think we’ve pulled it off, but only time will tell.”

Nor Eagle have also made some surprising choices when it comes to the art direction of the game. Unlike the slick, streamlined look of most contemporary games, the developer have found inspiration from scrapbooks. “It’s kind of ironic as I am normally a “less is more” kind of guy. I felt however that this project needed to be infused with some softer values. Some of our choices might fly in the face of well established design-conventions but I really think it works perfectly in this context.”

Among the elements used to give the game a friendly atmosphere is a game-host who is actually Larsen’s avatar. But the most surprising thing must be the developers’ claim that Fumbers can help fight Alzheimer’s disease: “Yes, I’m sure this is something that will raise a few eyebrows,” Larsen said. “It is not some kind of mumbo-jumbo magic trick. The fact of the matter is that the mechanics of the game fits hand in glove with what is called “cognitive reserve”. The theory, as I understand it, is that using your mind in particular ways is actually similar to giving your brain a workout. There are evidence to suggest this will prevent the effect of Alzheimer’s”. Despite all this, Larsen is eager to stress that Fumbers is first and foremost created to entertain. “It is a game clean and simple. The name derives from the words “fun” and “numbers” and this is really what Fumbers is all about. If anyone would like to refer to it as “an Alzheimer-fighting game for Steve Jobs” we won’t object too strongly though,” he finished laughingly.

Fumbers is compatible with the iPhone and iPod touch and is available worldwide through the iTunes App Store. It is priced at $ 1.99.

Nor Eagle is a Norwegian-based multimedia company founded in 1999. Nor Eagle has made its name domestically producing Corporate Videos and animations and is for the most of the time equal to its founder T. Benjamin Larsen.

###







Free Audio-Conference Call for ALS Patients on Best ALS Treatments to Live Longer, Easier


Calabasas Hills, CA (Vocus) January 22, 2010

The American Academy of Neurology and The ALS Association is offering a free audio-conference call at 5 p.m. ET, Thursday, on February 11, 2010 for people with ALS and their caregivers regarding the Academy?s new guidelines on the most effective treatments for ALS.

The call will help emphasize that a lot can be done to make life easier and longer for people with ALS. Important areas of care needing more research will also be highlighted.

The presenters include Robert G. Miller, M.D., neurologist and lead author of the Academy?s ALS guidelines. Presenters also include coauthors Carlayne E. Jackson, M.D., Edward J. Kasarskis, M.D., Ph.D., and Dallas A. Forshew, R.N.

A brief question-and-answer period will be available to patients and caregivers at the end of the call as time permits.

To join the audio-conference call with webinar capability, log on to https://alsa-events.webex.com/alsa-events/onstage/g.php?t=a&d=667887783. This is available to the first 1,000 registrants. If the webinar event is full, join the audio teleconference at:

Toll Free #: 1-877 669-3239

Toll #: 1-408-600-3600

Participant Passcode: 667 887 783 (then press #, #)

The American Academy of Neurology, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as, ALS, Parkinson?s disease, stroke, Alzheimer?s disease, dementia, West Nile virus and ataxia.

For more information about the American Academy of Neurology and its guidelines for treating ALS, visit http://www.aan.com.

The ALS Association is the only non-profit organization fighting Lou Gehrig?s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure.

For more information about The ALS Association, visit the organization?s Web site at http://www.alsa.org or call (800) 782-4747.

Contacts:

The ALS Association

Gary Wosk, Manager, Media Relations

(818) 587-2241

The ALS Association

Greg Cash, Director, Communications

(818) 587-2243

American Academy of Neurology

Rachel Seroka

(651) 695-2738

# # #







UCSF Neuroscience Building to Drive Advances Against Brain Diseases

San Francisco, CA (Vocus) January 22, 2010

UCSF is set to construct a major neuroscience building on its Mission Bay campus. The building will bring under one roof several of the world?s leading clinical and basic research programs seeking cures for intractable neurological disorders.

Approval to proceed with the funding and financing plan for the building was given today, January 21, 2010, by the University of California Board of Regents.

The five-story building will bring together clinicians, clinician-researchers and basic scientists to accelerate advances against such disorders as Alzheimer?s disease, Parkinson?s disease, multiple sclerosis, stroke, migraine, epilepsy, autism, mental retardation and cerebral palsy. It is a milestone in the evolution of UCSF?s world-class neuroscience enterprise.

?This culminates a 10-year dream,? says Nobel laureate Stanley B. Prusiner, MD, director of the Institute for Neurodegenerative Diseases, one of the programs that will be based in the building. ?This building will bring together some of the best scientists in the world to work on these very prevalent diseases of the brain. The opportunity for major progress is tremendous.?

The research space provided by this neuroscience building and the space in the adjacent Arthur and Toni Rembe Rock Hall neuroscience building will together constitute ?more than 400,000 square feet dedicated to studying these extremely complex, challenging diseases,? Prusiner says. ?UCSF Mission Bay will be one of the biggest neuroscience complexes in the world.?

?This building exemplifies UCSF?s commitment to discovery, education and patient care,? says UCSF Chancellor Sue Desmond-Hellmann, MD, MPH. ?It represents my vision for UCSF. In the face of these challenging financial times, it is imperative that we maintain our strategic vision and continue our leadership role in tackling the world?s devastating diseases.?

The building, known as the Neurosciences Laboratory and Clinical Research Building, will house the Institute for Neurodegenerative Diseases, the UCSF Department of Neurology and the W.M. Keck Foundation Center for Integrative Neuroscience at UCSF.

The first floor of the building will be occupied by clinicians and clinical researchers of the UCSF Memory and Aging Center, which is part of the Department of Neurology.

?We have an unprecedented opportunity with this building to establish a Manhattan project-like approach for moving in on these devastating neurological disorders,? says Stephen L. Hauser, MD, chair of the Department of Neurology.

?Clinicians treating patients with neurological conditions, clinician-researchers carrying out brain imaging and drug studies in patients, scientists studying the molecular and cellular basis of diseases, and scientists studying how the brain normally functions will be able to share their expertise, brainstorm, collaborate.?

?Ultimately, we want to be able to stop disease progression, repair damage that has already occurred and prevent disease from occurring in the first place,? he says.

?In MS, we?re currently planning the first clinical study to see if it can be halted before it begins.?

Collaborations with Silicon Valley, the biotech industry and the pharmaceutical industry will be key to this effort, Hauser says. Equally critical, he says, will be cultivating the next generation of neuroscience investigators and inspiring careers in translational medicine.

The world-class neuroscientists of the Keck Center, whose studies of brain function have shed light on how the human brain learns and remembers, how it sees, hears, moves the body?s limbs, and feels pain, will add another dimension to the research conducted in the building. Pioneers in the study of the brain?s ?plasticity,? or capacity to change, these scientsts focus on how brain cells work together to generate behaviors. Their intent is to learn enough about these processes that the brain could be taught to repair itself in patients born with disabilities, such as autism, or afflicted with disorders such as neurodegenerative diseases or stroke.

?Our goal in moving to this building is to help our colleagues understand how the brain works when it?s functioning well and for us to discover what happens in the whole system when brain function fails at the level of molecules and cells,? says Allison J. Doupe, MD, PhD, a psychiatrist and senior neuroscientist at the Keck Center.

The total project cost of the 237,000-square-foot building is $ 200 million. It will be built and owned by a private developer under a model intended to provide an alternative delivery structure for UC projects. UCSF, which owns the land, will ground lease the land to a developer and enter into a space lease for the building for a period of between 32-40 years, depending on bond market conditions. Lease costs will be paid by a combination of indirect costs from research grants, campus funds and philanthropy. UCSF plans to raise $ 95 million through philanthropy over the next five years. At the end of the lease period, ownership of the building, paid in full, will revert to UCSF. No state funds will be used to support the lease.

UCSF also plans to assess the potential to raise another $ 55 million over the same period to provide critical neuroscience program support, including funds for recruitment.

In their actions today, the Regents also approved $ 37 million to fund the drafting of preliminary plans, working drawings and basic site infrastructure to support the neuroscience building and three adjacent blocks of real estate at Mission Bay for future UCSF research buildings.

The building will house approximately 100 principal investigators and more than 500 additional researchers and staff, and be an engine for job creation. A dozen additional investigators who are experts in neurodegenerative diseases, drug discovery and drug synthesis will be recruited.

The LEED-silver certified building will be 25 percent more energy efficient than the base LEED-sustainability standard and achieve 20 percent water use reduction over the Energy Policy Act of 1992, through the use of such features as waterless urinals and occupant sensors.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Corinna Kaarlela, News Director

Source: Jennifer O’Brien (415) 476-2557

E-mail: jobrien(at)pubaff(dot)ucsf.edu

Web: http://www.ucsf.edu

###







New Study Reveals Protein Produced by Spleen Reduces Risk of Deadly Lung Infection


Manhasset, NY (Vocus) January 23, 2010

One to five percent of people who undergo surgery for gastrointesintal problems experience a potentially life-threatening condition: a temporary loss of oxygen that can set in motion a rogue inflammatory response that can lead to organ failure.

Ping Wang, MD, a scientist at The Feinstein Institute for Medical Research in Manhasset, NY, is testing the benefits of an experimental medicine that can clear away dying cells and reduce the risk for ischemia reperfusion injury. In a lead study published in the American Journal of Respiratory Critical Care Medicine, Dr. Wang and his colleagues used an experimental medicine called MFG-E8 on the heels of ischemia and found that it significantly lowered the risk for ischemia reperfusion injury, a condition caused when blood flow to the organ is interrupted (during surgery, injury or disease) and then re-established. Normally, when tissue suffers from a temporary loss of oxygen, the body makes an unusual response when the oxygen starts to flow again. It sets off an inflammatory response. These inflammatory cells actually target tissue and can trigger multiple organ failure. The lung is most susceptible to this type of injury, which is why in humans it can be deadly.

MFG-8 blocked the acute lung injury in an animal model of ischemic reperfusion. Fifty percent of the animals exposed to MFG-8 survived, according to Dr. Wang. MFG-8 is a protein normally produced by the spleen to enhance clearance of dying cells. The Feinstein scientists made a recombinant human protein. The idea to use the protein emerged after their studies showed that MFG-8 levels drop markedly on the heels of ischemia reperfusion. Spleen cells just can’t produce enough of the substance to clean up the dead or dying cells. If the cells are not removed — and this cellular garbage continues to accumulate — this cell death (called necrosis) can cause acute lung injury.

They found that the medicine helped clear out 90 percent of the dead cells in the hard-hit lung. It also reduced inflammation at the site. And the most hopeful news was that half of the animals survived the injury. The work in the laboratory will continue to address questions that need answering: Will the protein be harmful to patients? How much will be enough to protect against organ failure?

Right now, there is no approved medicine to treat ischemic reperfusion. Dr. Wang said that there are 50,000 to 100,000 deaths a year related to this intestinal injury.

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research (http://www.feinsteininstitute.org) is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson’s disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

Jamie Talan, science writer-in-residence

516-562-1232

# # #





Related Alzheimer Disease Press Releases